Abstract
Schizophrenia is a chronic and debilitating brain disorder. It is associated with increased mortality, primarily due to elevated cardio-metabolic risk. Affected patients have higher rates of obesity, metabolic syndrome and diabetes [1]. Intrinsic factors contributing to this increased risk include a shared underlying pathophysiology between schizophrenia and diabetes mellitus involving stress, inflammation and genetics. Extrinsic contributing factors include diet, lifestyle, health care access, low socioeconomic status and overburden of traditional diabetes risk factors. Antipsychotics are associated with an increased risk of obesity, metabolic syndrome and diabetes mellitus [1]. Appetite-regulating hormones, pharmacodynamics and alterations in glucose metabolism may underlie the negative effect of these medications. Reduction in diabetes risk is achieved by mitigating traditional risk factors. Non-pharmacologic and pharmacologic approaches to cardio-metabolic risk reduction may be helpful in these patients.
Keywords: Antipsychotics, diabetes mellitus, metabolic syndrome, obesity, schizophrenia.
Current Diabetes Reviews
Title:The Complex Inter-Relationship Between Diabetes and Schizophrenia
Volume: 13 Issue: 3
Author(s): Jeffrey Rado*
Affiliation:
- Department of Psychiatry and General Internal Medicine, Northwestern University, Chicago, IL,United States
Keywords: Antipsychotics, diabetes mellitus, metabolic syndrome, obesity, schizophrenia.
Abstract: Schizophrenia is a chronic and debilitating brain disorder. It is associated with increased mortality, primarily due to elevated cardio-metabolic risk. Affected patients have higher rates of obesity, metabolic syndrome and diabetes [1]. Intrinsic factors contributing to this increased risk include a shared underlying pathophysiology between schizophrenia and diabetes mellitus involving stress, inflammation and genetics. Extrinsic contributing factors include diet, lifestyle, health care access, low socioeconomic status and overburden of traditional diabetes risk factors. Antipsychotics are associated with an increased risk of obesity, metabolic syndrome and diabetes mellitus [1]. Appetite-regulating hormones, pharmacodynamics and alterations in glucose metabolism may underlie the negative effect of these medications. Reduction in diabetes risk is achieved by mitigating traditional risk factors. Non-pharmacologic and pharmacologic approaches to cardio-metabolic risk reduction may be helpful in these patients.
Export Options
About this article
Cite this article as:
Rado Jeffrey*, The Complex Inter-Relationship Between Diabetes and Schizophrenia, Current Diabetes Reviews 2017; 13(3) . https://dx.doi.org/10.2174/1573399812666161220144740
DOI https://dx.doi.org/10.2174/1573399812666161220144740 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The HCMV Chemokine Receptor US28 is a Potential Target in Vascular Disease
Current Drug Targets - Infectious Disorders An Integrated and Disease-Oriented Growth Factor-Regulated Signal Transduction Network
Current Molecular Medicine The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Current Rheumatology Reviews HMGB-1 as a Target for Inflammation Controlling
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design Diagnostic Value of Postprandial Triglyceride Testing in Healthy Subjects:A Meta-Analysis
Current Vascular Pharmacology Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry Mitochondrial-Associated Metabolic Changes and Neurodegeneration in Huntingtons Disease - from Clinical Features to the Bench
Current Drug Targets Editorial: Modifying Cardiovascular Risk Factors: Acquired Topics and Emerging Concepts
Current Pharmaceutical Design Severe Preeclampsia
Current Women`s Health Reviews Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges
Protein & Peptide Letters Editorial [Hot Topic: Trends in Vascular Biology; Functional Restoration of Damaged Endothelium (Executive Editors: J.A. Rodriguez-Feo and G. Pasterkamp)]
Current Pharmaceutical Design Cardiovascular Risk, Inflammation and Physical Activity in Rheumatoid Arthritis
Current Rheumatology Reviews Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) 24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes
Current Hypertension Reviews Specific Nutritional Needs for Children: Are Children Small Adults?
Current Pediatric Reviews Excessive Matrix Metalloproteinase Activity in Diabetes: Inhibition by Tetracycline Analogues with Zinc Reactivity
Current Medicinal Chemistry Metabolic Syndrome Components in Murine Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Obesity and Cardiovascular Physiology: Impact of some Pharmacological Agents
Current Vascular Pharmacology